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Abstract
Introduction and Objective Pharmacovigilance require-
ments for biologics mandate that EU Member States shall
ensure that any biologic that is the subject of a suspected
adverse drug reaction (ADR) is identifiable by brand name
and batch number. Recent studies showed that brand name
identification is well established, whereas batch numbers are
(still) poorly reported. We evaluated information-recording
systems and practices in theDutch hospital setting to identify
determinants for brand name and batch number recording as
well as success factors and bottlenecks for traceability.
Methods We surveyed Dutch hospital pharmacists with
an online questionnaire on systems and practices in hos-
pitals for recording brand names and batch numbers.
Additionally, we performed an analysis of the traceability
of recombinant biologics in spontaneous ADR reports
(received between 2009 and 2014) from the Netherlands
Pharmacovigilance Centre Lareb.
Results The survey showed that brand names are not
routinely recorded in the clinical practice of Dutch hospi-
tals, whereas batch numbers are poorly recorded. Seventy-
six percent of the 1523 ADR reports for recombinant
biologics had a traceable brand name whereas 5 % of these
reports contained a batch number. The results suggest a
possible relationship between the availability of brand and
batch number information in clinical practice and the
inclusion of this information in ADR reports for biologics.
Conclusion The limited traceability of brand names and
batch numbers in ADR reports may be primarily caused by
the shortcomings in the recording of information in clinical
practice. We recommend efforts to improve information-
recording systems as a first step to improve the traceability
of biologics in ADR reporting.
Key Points
Brand names are not routinely recorded in Dutch
clinical practice for medicinal products dispensed
and administered to patients; moreover, batch
numbers are poorly recorded overall.
Product and batch information recording in clinical
practice for biologics is necessary for the retrieval of
detailed exposure information in case of an adverse
drug reaction.
Shortcomings in the recording and tracing of
exposure information in clinical practice may be
associated with the limited traceability of biologics
in ADR databases such as EudraVigilance.
Electronic supplementary material The online version of this
article (doi:10.1007/s40264-015-0383-8) contains supplementary
material, which is available to authorized users.
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1 Introduction
Biologics differ from small molecule medicines in their
highly complex structures and sensitivity to changes in the
manufacturing process [1, 2]. These distinctive properties
for biologics have consequences for the authorisation of
follow-on biologics (biosimilars), but also for maintaining
constant product quality and safety profiles throughout the
lifecycle of a biologic [3, 4]. Manufacturing variability
between and within products over time may result in pre-
viously unobserved adverse drug reactions (ADRs) [5, 6].
For this reason, biologics are subject to specific pharma-
covigilance requirements, which mandate that EU Member
States take all appropriate measures to ensure that any
biologic that is the subject of a suspected ADR report needs
to be identifiable by brand name and batch number [7].
Adequate availability of this exposure information is nec-
essary to timely link an emerging product safety issue to
the correct product and batch [8].
In the EU, national competent authorities (NCAs) for
pharmacovigilance and marketing authorisation holders
(MAHs) collect reports of suspected ADRs at the national
level, which are then aggregated in EudraVigilance, the
EU ADR database that is maintained by the European
Medicines Agency (EMA), to support signal detection and
analysis. A recent study by Cutroneo et al. in the Italian
ADR database showed that for 94.8 % of the entries for
biologics, identifiable brand names were reported [9]. For
ADR reports for biologics for which a biosimilar was on
the market, this number was even higher (98.7 %). A
study by Vermeer et al. in EudraVigilance showed that
96.2 % of the entries for suspected biologics were iden-
tifiable by brand name [10]. In contrast, both the Cutro-
neo et al. and the Vermeer et al. analyses showed that
batch number reporting was poor (8.6 and 21.1 %,
respectively).
Previous studies quantifying the traceability and iden-
tifiability of biologics in spontaneous reporting databases
concluded that the traceability of biologics is not ade-
quately ensured and encouraged stakeholders to undertake
efforts to improve the current situation. However, factors
that may contribute to the lack of traceability have not been
studied in detail yet. In the present study, we therefore
aimed to identify determinants for brand name and batch
number recording as well as critical success factors and
bottlenecks for ensuring the traceability of biologics in
ADR reporting. We used the Dutch hospital setting as a
case to evaluate the information-recording practices, as the
hospital setting plays a central role in the distribution
process of most biologics, and evaluated influencing fac-
tors for the reporting of brand names and/or batch numbers
in ADR reports for biologics.
2 Methods
We approached this study with a mixed quantitative and
qualitative method. We first evaluated the information-
recording systems and practices that are in place in the
Dutch hospital setting for brand name and batch number
recording, by surveying hospital pharmacists about infor-
mation-recording systems and practices within their hos-
pital. Secondly, we performed a comprehensive analysis of
the traceability of biologics in spontaneous ADR reports
from the Dutch ADR database at the Netherlands Phar-
macovigilance Centre Lareb, comparing ADR reports
originating from the hospital setting with other report
sources.
2.1 Assessment of In-Hospital Information-
Recording Systems and Practices
2.1.1 An Overview of the Hospital Setting
In general, three processes can be distinguished within the
hospital setting [11–13].
(i) The drug distribution process. The drug distribution
process starts with the distribution of the drug from
the manufacturing plant to the wholesaler and, next, to
the hospital pharmacy.
(ii) The healthcare process. When a drug has been
delivered to the hospital pharmacy, it enters the
healthcare process, which starts with the physician
prescribing a drug, the hospital pharmacist dispensing
the drug, a physician or nurse administering the drug
and the patient receiving the drug and being moni-
tored by the physician.
(iii) The information-recording process. At different
steps in the healthcare (and distribution) process,
information-recording systems may be used to record
information about a medicinal product; for example,
by scanning barcodes on the outer package.
In the Netherlands, different types of information-
recording systems can be identified: hospital pharmacy
information systems (HPIS) at the dispensing phase, elec-
tronic medication administration records (eMAR) at the
administration phase and the electronic health records
(EHR) of the patient, which capture a variety of adminis-
trative and medical data about the patient.1 These infor-
mation-recording systems may or may not exchange
information with each other or be incorporated in one
1 Another system that is in place in Dutch hospitals is the
computerised physician order entry (CPOE) used for prescribing a
drug. This system is not further discussed in this study because it
captures what is prescribed and not which drug has actually been
dispensed/administered to the patient.
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integral system [14]. Additionally, hospital pharmacists in
the Netherlands keep a record within the pharmacy of
medicinal products that are prepared for administration to a
specific patient. This record, called the compounding pro-
tocol, may provide another opportunity to record and trace
back medicinal product information (at least for the bio-
logics that are prepared for administration in the hospital
pharmacy) [15].
2.1.2 Survey on Information-Recording Systems
and Practices in the Hospital Setting
The overview described in the previous section provided
the framework for a survey among Dutch hospital phar-
macists. The survey focused on systems and practices in
hospitals for the recording and the availability of medicinal
product information, such as brand names and batch
numbers (for biologics in particular). The survey was
conducted with an online questionnaire that was sent to all
members of the Netherlands Association of Hospital
Pharmacies representing 93 hospitals in the Netherlands
(see electronic supplementary material 1). The question-
naire consisted of three sections with a total of 36 ques-
tions, comprising a mix of multiple choice and open
questions. The questionnaire started with questions about
the information-recording systems that are in place in
Dutch hospitals, followed by questions about the experi-
ence of the hospital pharmacists with ADR reporting for
biologics and, finally, the questionnaire asked for personal
recommendations on how to improve the traceability of
biologics in clinical practice. The last section consisted of
open questions that could be responded to voluntarily.
2.2 Analysis of ADR Data from The Netherlands
Pharmacovigilance Centre Lareb
2.2.1 Study Sample
For the analysis of ADR reports in the Netherlands, we
used a pre-defined list of recombinant biologics to select
relevant reports. The list of recombinant biologics was
created based on an extraction of all centrally authorised
medicinal products found in the EMA database of Euro-
pean Public Assessment Reports (EPARs) on November
30, 2014. A product was included on our list if recombinant
technology or cell lines were mentioned for the description
of the manufacturing process in Section 2 of the Summary
of Product Characteristics (SmPC) entitled ‘‘Qualitative
and quantitative composition’’. Seven recombinant bio-
logics (four somatropins, one epoetin alfa, one insulin
human and one filgrastim) that were authorised prior to
1995 were also added to the list because they are still
commonly used in clinical practice in the Netherlands.
Recombinant vaccines were not included in this study. The
146 recombinant biologics used for this study were cate-
gorised in 11 mechanistic product classes (see electronic
supplementary material 2).
Based on ATC codes, we extracted spontaneous reports
of suspected ADRs for the products on our sample list
received between January 01, 2009 and December 31, 2014
from the database of The Netherlands Pharmacovigilance
Centre Lareb. For this analysis, we only included sponta-
neous ADR reports that have been directly reported to the
Netherlands Pharmacovigilance Centre Lareb. PL/SQL
Developer Version 8.0.41514 was used for the extraction of
ADR data from the Dutch ADR database.
2.2.2 Data Classification and Outcome Analysis
Brand name and batch number entry fields were reviewed to
determine whether the brand name was identifiable and
whether reported batch numbers referred to valid entries (e.g.
to exclude false entries such as ‘‘unknown’’ or ‘‘?’’). The
traceability of biologics in ADR reports was assessed based
on the number of reports that included a brand name and
batch number. Data were stratified by reporter type, the year
in which the report was received and product class. All
values are presented as absolute numbers and proportions.
3 Results
3.1 Assessment of In-Hospital Information-
Recording Systems and Practices
3.1.1 Evaluation of the Information-Recording Systems
and Practices in the Hospital Setting
The online survey among hospital pharmacists had a
response rate of 37 % (34 out of 93 hospitals). Twenty-
seven out of 34 (79 %) hospital pharmacists responded that
brand names are routinely recorded in the HPIS, which is
only accessible to hospital pharmacists and technicians as
indicated by 33 (97 %) respondents and to a smaller extent
to physicians as indicated by 14 (41 %) respondents
(Table 1). Twenty-five (74 %) hospital pharmacists indi-
cated that eMAR is in place in their hospital. Fifteen out of
these 25 (60 %) hospitals with eMAR responded that brand
names are routinely recorded in eMAR during the admin-
istration phase. Twenty-two out of all 34 (65 %) respon-
dents indicated that brand names are routinely recorded in
the EHR. A total of seven (21 %) hospitals do not record
brand names routinely in any of the available information-
recording systems that are in place. None of the respon-
dents indicated that batch numbers are routinely recorded
in the HPIS, eMAR or EHR (Table 1).
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In addition to the information-recording systems, 23
(68 %) respondents indicated that brand names are rou-
tinely recorded in the compounding protocol, whereas all
34 (100 %) respondents indicated that batch numbers are
routinely recorded in the compounding protocol. The
information in the compounding protocol is, however, only
available to hospital pharmacists and technicians as indi-
cated by all respondents.
For comparison, a post-hoc exploratory survey outside
the hospital setting among 56 community pharmacists
indicated that 51 (91 %) community pharmacists routinely
record brand names in their community pharmacy infor-
mation system for medicinal products dispensed to
patients.
3.1.2 Bottlenecks and Potential Solutions
for the Traceability of Biologics
The open questions about the opinions of hospital phar-
macists about the main bottlenecks and possible solutions
for the traceability of biologics in clinical practice resulted
in 26 responses. The main reported bottleneck that hampers
the traceability of biologics in clinical practice is that batch
number information is not encoded in barcodes and can
therefore not automatically be recorded in information-
recording systems, as mentioned by 19 (73 %) hospital
pharmacists. Ten (38 %) hospital pharmacists mentioned
that the barcodes that are present are often not available on
the single unit dose and can therefore not be scanned for
information-recording purposes. Eight (31 %) hospital
pharmacists indicated that due to the lack of batch number
entry fields in current information-recording systems, it is
not possible to (manually) record batch numbers.
The hospital pharmacists who provided potential solu-
tions were fairly in agreement; 19 out of 26 (73 %) respon-
dents indicated that barcodes with encoded batch numbers or
a similar method could offer a robust solution by facilitating
(automatic) recording of batch number information in the
information-recording systems. Moreover, 10 (38 %) hos-
pital pharmacists specifically called for the provision of
barcodes on the single unit dose, since this is the packaging
that needs to be scanned during the dispensing phase in HPIS
and during the administration phase in eMAR.
3.1.3 Awareness
The results of the hospital pharmacy survey also showed a
limited awareness about the requirement to report the brand
name and the batch number in ADR reports for biologics.
Six out of 34 (18 %) hospital pharmacists indicated that
they are unaware of the need to include brand names in
ADR reports for biologics, whereas four (12 %) hospital
pharmacists indicated that they do not see the purpose for
reporting the brand names. When it comes to batch number
reporting, 14 (41 %) hospital pharmacists responded that
they were not aware that they should include batch num-
bers for ADR reports for biologics, whereas two (6 %)
respondents indicated that they do not see the need to
include batch numbers in ADR reports for biologics.
3.2 Analysis of ADR Data from The Netherlands
Pharmacovigilance Centre Lareb
The Netherlands Pharmacovigilance Centre Lareb received
43,907 spontaneous ADR reports in the study period, in
which 1523 recombinant biologics from our sample list
were reported as suspected drugs. For 76 % of these bio-
logics that were the subject of a suspected ADR report, a
brand name was identifiable, whereas 5 % of the ADR
reports contained a batch number.
3.2.1 Reporter Type Analysis
Physicians and nurses accounted for the majority (57 %) of
the ADR reports from our study sample, whereas hospital
pharmacists accounted for 5 % of the entries. The
remaining 38 % of the ADR reports were received from
community pharmacists (16 %), patients (15 %), general
practitioners (5 %) and unclassified (2 %).
As shown in Table 2, community pharmacists are most
likely to report a brand name (96 %), followed by patients
(87 %), general practitioners (86 %), hospital pharmacists
(69 %) and physicians and nurses (68 %). However, when
it comes to batch number reporting, hospital pharmacists
are most likely to report batch numbers (36 %), whereas
physicians and nurses are least likely to report a batch
number (3 %).









HPIS 34 27 (79) 0 (0)
eMAR 25 15 (60) 0 (0)
EHR 34 22 (65) 0 (0)
HPIS Hospital pharmacy information system, eMAR electronic medication administration record, EHR electronic health record
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3.2.2 Reporting Over Time
When the ADR reporting data were stratified by year, no
visible increase over time in brand name or batch number
reporting and no change after the introduction of the new
pharmacovigilance legislation was observed (Fig. 1).2
3.2.3 Product Class Analysis
For each product class, we analysed the total numbers of
ADR reports and the percentages of brand name and batch
number identification (Table 3). More than half of the
ADR reports for recombinant biologics in the Dutch ADR
database concerned monoclonal antibodies. We also
observed class-specific differences for brand name report-
ing. Batch number reporting varied from 0 % to a maxi-
mum of 10 % between different product classes.
The product class other consisted of recombinant pro-
teins such as teriparatide, for example. Only a small
number of ADR reports (n = 37) were received for bio-
logics for which a biosimilar is on the market in the
Netherlands (somatropin, epoetin alfa and filgrastim),
which did not allow for an analysis of the traceability of the
brand name for these specific product classes.
4 Discussion
4.1 Main Findings
Our analysis showed that brand names are not routinely
recorded in the clinical practice of Dutch hospitals,
whereas batch numbers are poorly recorded. This prevents
adequate traceability of brand and batch information for the
purpose of ADR reporting. The results from the survey
together with the ADR data analysis suggest a possible
relationship between the availability of (and thus the ability
to trace) brand name and batch number information in
clinical practice and the inclusion of this information in
ADR reports for biologics. The main bottlenecks for
ensuring the traceability of biologics in ADR reporting to
the level of the batch number are the absence of adequate
information-recording systems that allow tracing of this
information and missing information on the product or
single unit dose.
4.2 Brand Name Traceability
As the findings from our study indicated, brand names are
not routinely recorded in the information-recording sys-
tems in the hospital setting. This could explain why
















Fig. 1 Brand name and batch number reporting over time: traceabil-
ity of spontaneous adverse drug reaction (ADR) reports of recombi-
nant biologics received by the Netherlands Pharmacovigilance Centre
Lareb (2009–2014)
Table 2 Brand name and batch number reporting by reporter type of adverse drug reaction (ADR) reports of recombinant biologics received by
the Netherlands Pharmacovigilance Centre Lareb (2009–2014)
Reporter type ADRs reported [n (%)a] Brand names reported [n (%)b] Batch numbers reported [n (%)b]
Hospital: physician/nurse 866 (57) 587 (68) 13 (2)
Hospital: pharmacist 78 (5) 54 (69) 28 (36)
Community: GP 78 (5) 67 (86) 2 (3)
Community: pharmacist 239 (16) 229 (96) 17 (7)
Patient 223 (15) 193 (87) 11 (5)
Unclassified 39 (2) 22 (56) 3 (8)
Total 1523 (100) 1152 (76) 74 (5)
GP general practitioner (community setting)
a These percentages are proportions of the total of 1523 ADR reports
b These percentages represent the proportion of the total number of ADRs reported by the reporter type in the respective row
2 The pharmacovigilance legislation was implemented in the Nether-
lands in January 2013 (https://zoek.officielebekendmakingen.nl/stb-
2013-21.html [in Dutch]).
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hospital pharmacists include brand names in ADR reports
in only 68–69 % of the cases. This is in contrast to the
percentage of brand name reporting for reporter types
outside the hospital setting, for example the community
pharmacists, who include brand names in 96 % of the
cases. The post-hoc exploratory survey among community
pharmacists referred to in the results section supported
these findings: 91 % of the community pharmacists indi-
cated that brand names are routinely recorded in the
community pharmacy information system for medicinal
products dispensed to patients.
This may also explain the difference between product
classes observed in Table 3. An ADR report for the mono-
clonal antibodies, which in the Netherlands is mostly dis-
pensed in the hospital setting, has identifiable brand names in
67 %of the cases. However, ADR reports for insulins, which
are mostly dispensed in the community setting, have iden-
tifiable brand names in 91 % of the cases. An explanation for
why the systematic recoding of brand names is not always
common practice in the hospital setting (as compared with
the community setting) could be the Dutch reimbursement
system for medicines. Hospitals are financially compensated
according to agreed budget allocations for a specific type of
treatment; therefore, brand names are not necessarily
required for invoicing purposes [16]. However, reimburse-
ment in the community pharmacy setting is based on a
reimbursement system for specific brands, requiring a
comprehensive system to record which specific brand of the
medicinal product has been dispensed [17].
4.3 Batch Number Traceability
A possible association between the availability of medici-
nal product information and the inclusion of this informa-
tion in ADR reports is also observed for batch numbers. As
shown by the results from the pharmacist survey, batch
numbers are not routinely recorded in hospital information-
recording systems. This means that the batch number
information is lost and cannot be traced after the (primary)
package of the medicinal product has been discarded [18].
However, our study also found that batch numbers are
routinely recorded in the compounding protocol for
medicinal products that are prepared for administration in
the hospital pharmacy, which supports the findings from a
previous study [15]. Although this only concerns biologics
that are compounded in the hospital pharmacy, it was
observed that hospital pharmacists (who are the only
healthcare professionals with direct access to this infor-
mation) are most likely to include batch numbers in ADR
reports (36 %) compared with other reporter types. We
believe that the majority of ADR reports from hospital
pharmacists with identifiable batch numbers concern bio-
logics that are prepared in the hospital pharmacy, since
these reports mainly concern biologics that are supplied in
formulations that require an additional preparatory step
before administration to the patient (e.g. powder form).
4.4 Limitations
There are several limitations that need to be considered
when interpreting the results of this study. It should be
noted that there is only a limited number of ADR reports
available for the sample list of recombinant biologics
included in this analysis, which does not allow for exten-
sive data analysis. In addition, we only included recombi-
nant biologics in the ADR data analysis. However, we have
no reasons to assume that the ADR reporting quality would
have strongly diverged when including data for non-re-
combinant biologics as well.
There are certain limitations that apply to online surveys
like the one used in this study; for example, some questions
may be misinterpreted or filled in incorrectly due to a lack
Table 3 Brand name and batch
number reporting of
recombinant biologics by
product class in adverse drug










Somatropins 4 3 (75) 0 (0)
Epoetins 43 40 (93) 0 (0)
Filgrastims 19 17 (89) 1 (5)
Follitropins 21 21 (100) 1 (5)
Monoclonal antibodies 797 536 (67) 45 (6)
Insulins 180 164 (91) 18 (10)
Interferons 51 45 (88) 3 (6)
Antihaemophilic factors 52 52 (100) 1 (2)
Fusion proteins 232 178 (77) 5 (2)
Enzymes 2 1 (50) 0 (0)
Other 122 95 (78) 0 (0)
Total 1523 1152 (76) 74 (5)
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of understanding or time constraints. We offered several
open questions and explanatory text fields to allow
responders to provide additional information, explain their
answers or to indicate if they do not know the answer to a
question. However, when looking at the answers we
believe that there was a clear pattern emerging from the
respondents. We have no reason to assume that there was a
non-response bias.
Although the generalisability of the results of this study
to European practice is potentially limited considering the
expected heterogeneity in national policies and guidelines,
we believe that the Netherlands provides a good case study
to demonstrate the importance of information-recording
systems in current pharmacovigilance activities and the
challenges and bottlenecks encountered. It would, how-
ever, be useful to conduct comparable analyses in other EU
Member States. A detailed ADR data analysis in other
Member States could provide new insights into informa-
tion-recording systems and practices, and identify more
bottlenecks and success factors for the traceability of
biologics.
4.5 Technical Solutions to Improve Traceability
in Clinical Practice
The online questionnaire among hospital pharmacists
showed that the majority of hospital pharmacists expressed
the need for barcodes with encoded batch number infor-
mation on the single unit dose to improve the traceability
of biologics. This would allow electronic recording of
medicinal product information (such as batch numbers) of
individual packages throughout the supply chain; for
example, bedside scanning at the administration site. The
implementation of a new ‘standard’ barcode may impose
challenges to the current ICT infrastructure of stakeholders
involved and may require a change of practice. Finding
synergies with other initiatives that may benefit from a new
barcode may therefore be critical. For example, in a full
track-and-trace system, a barcode containing batch number
information applied to the single unit dose (often the pri-
mary package) may provide opportunity for synergies with
other important topics, such as improvement of the effi-
ciency of batch recalls, optimisation of inventory man-
agement in pharmacies, increased transparency of the
distribution chain and the reduction of medication errors.
The GS1 Data Matrix is a two-dimensional barcode that
allows batch number encoding and will be mandatory by
2018 as part of the Falsified Medicines Directive. The
Directive, however, states that the GS1 Data Matrix, in
which the inclusion of the batch number will be mandatory,
will only be applied to the outer package (secondary
packaging) [19–21].
4.6 Awareness
Our study showed that a lack of awareness still could play a
role in the poor traceability of biologics in ADR reporting,
which is a frequently stated cause in the literature [22].
However, as our analysis in the Netherlands shows, apart
from raising awareness, improvements in the area of
healthcare systems and practices for recording and tracing
medicinal product information are fundamentally required
as this could be the root causes for the poor traceability of
biologics in ADR reporting and therefore needs to be
addressed in tandem.
5 Conclusion
In conclusion, this study showed that, in the Netherlands,
brand names are not routinely recorded in clinical practice
and batch numbers are poorly recorded. These findings
suggest that the limited traceability of brand names and
batch numbers in ADR reports for biologics may be pri-
marily caused by the shortcomings in the recording and
tracing of information in clinical practice. Although a lack
of awareness may contribute to this issue, efforts to address
the systems for information recording and sharing in clin-
ical practice are needed. Furthermore, the implementation
of a barcode on the single unit dose that contains both
brand name and batch number information may be needed
as a first step to improve the traceability of (biological)
medicinal products in clinical practice. Concerted actions
such as these can help to build a system that is able to
support the achievement of the public health objectives that
are the reason for current regulations for the pharma-
covigilance of biologics in Europe. From a broader per-
spective, the findings presented in this study should also
highlight the need for EU policy makers to evaluate
national regulatory instruments prior to the implementation
of new regulations and to assess how EU regulations can be
used at the national level in an appropriate and pragmatic
manner.
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